Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Why Companies Should Hire Aspiring MSLs (and How)
Summary
In this episode, Alyson Evans joins Tom Caravela to discuss the evolving landscape of the MSL role. Alyson shares her career journey and offers insights on hiring practices, comparing the strengths of aspiring versus experienced MSLs. She provides comprehensive advice for those looking to break into the field, highlighting the importance of networking and purposeful diversity in hiring. Alyson also predicts future trends that could shape the MSL role. The episode wraps up with final thoughts and actionable advice for aspiring MSLs, encouraging listeners to remain proactive and engaged in their career development.
My guest today is Alyson Evans, Director, Medical Affairs with Sirtex Pharmaceuticals. Alyson discusses why companies should consider hiring aspiring MSLs.
She shares…
π Why she considers hiring aspiring MSLs and what her experience has been
π The advantages and disadvantages of hiring aspiring MSLs
π How to go about hiring aspiring MSLs
π What “purposeful diversity hiring” is
π What advice she has for aspiring MSLs looking to land a role as a Medical Science Liaison
MSL role, Medical Science Liaison, aspiring MSLs, networking in medical affairs, diversity hiring in pharmaceuticals
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary